In patients with high bleeding risk, 1 vs. ≥3 mo of DAPT after complex or noncomplex PCI did not differ for clinical events

Manoj Kesarwani

doi:10.7326/J22-0076

In patients with high bleeding risk, 1 vs. ≥3 mo of DAPT after complex or noncomplex PCI did not differ for clinical events

Ann Intern Med. 2022 Oct;175(10):JC112. doi: 10.7326/J22-0076. Epub 2022 Oct 4.

Author

Manoj Kesarwani¹

Affiliation

¹ University of California, Davis School of Medicine, Sacramento, California, USA (M.K.).

PMID: 36191320
DOI: 10.7326/J22-0076

Abstract

Valgimigli M, Smits PC, Frigoli E, et al. Duration of antiplatelet therapy after complex percutaneous coronary intervention in patients at high bleeding risk: a MASTER DAPT trial sub-analysis. Eur Heart J. 2022:43:3100-14. 35580836.

Publication types

Comment

MeSH terms

Drug Therapy, Combination
Hemorrhage / chemically induced
Humans
Percutaneous Coronary Intervention* / adverse effects
Platelet Aggregation Inhibitors* / adverse effects
Treatment Outcome

Substances

Platelet Aggregation Inhibitors